TLDR: Bayosthiti AI, the Indian subsidiary of Biostate AI, has partnered with Narayana Health to develop the world’s largest cardiac AI dataset tailored for Indian populations. This landmark 12,000-patient study aims to create the first AI models capable of predicting cardiovascular disease in South Asians years before conventional diagnosis, addressing a critical ‘Data Gap’ in global healthcare.
BENGALURU, India & HOUSTON – October 29, 2025 – In a significant stride towards revolutionizing cardiovascular care in India, Bayosthiti AI, the Indian subsidiary of Biostate AI, a leader in AI-driven molecular diagnostics, has announced a strategic partnership with Narayana Health, one of the globe’s largest cardiac care networks. This collaboration is set to establish the world’s most extensive India-specific cardiac AI dataset, leveraging molecular data from 12,000 Indian patients.
The initiative directly confronts a long-standing ‘Data Gap’ in medical diagnostics. Historically, most cardiovascular risk algorithms have been developed using patient data predominantly from European and American populations. This presents a critical challenge for South Asian populations, who are known to develop heart disease 5-10 years earlier than their Western counterparts and exhibit distinct genetic and molecular patterns. The reliance on Western-calibrated tools has frequently led to missed diagnoses, delayed detection, and preventable deaths among the estimated 65 million Indians suffering from coronary artery disease.
The joint effort between Bayosthiti AI and Narayana Health aims to bridge this disparity by developing the first AI models specifically designed to predict cardiovascular disease within Indian populations. The study will meticulously analyze complete RNA profiles – the real-time active instructions cells execute – to detect early indicators of heart disease months or even years before structural damage becomes apparent through traditional diagnostic methods.
This partnership combines three crucial elements: Biostate AI’s proprietary BIRT™ (Barcode-Integrated RNA Technology) and advanced generative AI platforms, Narayana Health’s extensive cardiac care network and patient data, and the focused expertise of Bayosthiti AI as India’s first AI-first healthcare company. Bayosthiti AI is pioneering ‘Lifetime Health Management’ through 24/7 AI Clinical Assistants and AI Scientists, catering to patients, clinicians, and researchers.
Also Read:
- Mark Cuban’s Cost Plus Drugs Partners with Medchat.ai to Integrate AI for Enhanced Customer Support and Affordability
- Insilico Medicine’s AI Engine Accelerates GLP1R Peptide Design for Diabetes Treatment in Record Time
The ultimate goal of this collaboration is to enable precision medicine tailored for India, the world’s second-largest population, with the potential to prevent heart attacks years before they occur. For Biostate AI, this partnership underscores its strategy of integrating breakthrough molecular technologies with AI to tackle persistent healthcare challenges, positioning Bayosthiti to address the needs of 1.4 billion people while developing capabilities that can be scaled globally.
